Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase

Oral azacitidine (oral-Aza) treatment results in longer median overall survival (OS) (24.7 vs. 14.8 months in placebo) in patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy. The dosing schedule of oral-Aza (14 days/28-day cycle) allows for low exposure of Aza for an...

Full description

Bibliographic Details
Main Authors:	Jeyaraju, DV, Alapa, M, Polonskaia, A, Risueño, A, Subramanyam, P, Anand, A, Ghosh, K, Kyriakopoulos, C, Hemerich, D, Hurren, R, Wang, X, Gronda, M, Ahsan, A, Chiu, H, Thomas, G, Lind, EF, Menezes, DL, Schimmer, AD, Hagner, PR, Gandhi, A, Thakurta, AG
Format:	Journal article
Language:	English
Published:	Ferrata Storti Foundation 2023

Extended exposure to low doses of azacitidine induces differentiation of leukemic stem cells through activation of myeloperoxidase

Similar Items